Home Our Medicines
OUR MEDICINES
Asiakare Ltd.'s Portfolio
ASIAKARE LTD. HAS A LARGE PORTFOLIO IN THE FOLLOWING CATEGORIES:
Essential and Niche IV Drugs
Drugs for Rare Diseases
Antidotes and Antivenoms
Orphan Drugs
ESSENTIAL DRUGS MISSING IN ASIA PACFIC
“Essential medicines are those that satisfy the priority health care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness.” (quoted from WHO)
DRUGS IN SHORTAGE
A drug can be in shortage or discontinued for different reasons: production issues, decrease of promotion by the manufacturer due to low profit, regulatory obstacles to reach a territory, etc.
ORPHAN DRUGS
Medicines to treat orphan diseases might be very difficult to procure in a country, either because of import regulation and/or because of lack of awareness. Some drugs are widely used in Europe, America, Japan and Australia but suffer from supply issues in APAC area.
DRUGS WITH HYBRID COMMERCIALIZATION PROCESS
As an example, the procurement of general antidotes or military/CBRN drugs is also handled by non-hospital actors like poisons centers, emergency services or governmental bodies. This system creates extra layers of complexity to source and import such medicines.
THE ESSENTIAL DRUG DISRUPTION STORY
Essential drugs are often experiencing a sudden drop in availability following discontinuation from originator due to low profitability or business restructuring. Most of those drugs are well-known established medicines reaching the end of their life cycle.
The usual scenario arises when a Drug Originator managed to retain their market share throughout the whole drug life cycle. At decline stage, and in case of discontinuation from the manufacturer, then nobody is left or big enough to take over.
With fewer manufacturers and less production capacity around -> the supply of such drugs is under pressure and leads to discontinuation, shortages, price hike or no launch in some territories and no availability at all anymore.
This scenario becomes a major health concern when such a drug is an ESSENTIAL DRUG.
Unregistered regulatory pathways (called "special access" or "Patient Name") become then vital to fix the situation and to bring the medicine to patients. Then registration of the medicine would bring back a sustainable solution.